Clinical breast cancer最新文献

{"title":"CTSG Suppresses Breast Cancer Progression by Inhibiting the EGFR/ERK Signaling Pathway and Enhancing CD8⁺ T Cell Activation","authors":"Yue Pan,&nbsp;Chenhui Zheng,&nbsp;Danni Zheng,&nbsp;Yin Pan","doi":"10.1016/j.clbc.2026.07.027","DOIUrl":"10.1016/j.clbc.2026.07.027","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer (BC), the most common female malignancy, has metastasis as its main cause of mortality. Cathepsin G (CTSG) is involved in tumorigenesis and immunity. This study explores the role of CTSG in BC progression and CD8 + T cell regulation.</div></div><div><h3>Methods</h3><div>Differentially expressed genes and proteins (DEGs/DEPs) were analyzed using Limma, and core genes were screened using Random Forest (RF) and Least absolute shrinkage and selection operator (LASSO). CTSG expression was analyzed using GSE36295, the Cancer Genome Atlas (TCGA), reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and western blot. Cell viability, proliferation, cell cycle, migration, and invasion were detected using Cell Counting Kit-8 (CCK8), 5‑Ethynyl‑2ʹ‑deoxyuridine (EdU), flow cytometry, and Transwell assays, respectively. Sphere diameter was analyzed via sphere formation assay. Downstream mechanisms were examined using western blot, CCK8, flow cytometry, and Transwell assays. CD8 + T cell activity was examined using EdU, western blot, and flow cytometry.</div></div><div><h3>Results</h3><div>A total of 177 genes overlapped between GSE36295 DEGs and PDC000173 DEPs. CTSG was the hub gene identified by RF and LASSO. CTSG expression was significantly reduced in BC (<em>P</em> &lt; 0.01). CTSG overexpression suppressed cell viability, proliferation, migration, invasion, sphere formation, and CD44 and CD133 expression (<em>P</em> &lt; 0.01). CTSG up-regulation inhibited epidermal growth factor receptor (EGFR)/extracellular signal-regulated kinase (ERK) signaling axis and reduced cancer cell malignancy (<em>P</em> &lt; 0.01). CTSG overexpression activated CD8 + T cells via EGFR/ERK inhibition, enhancing their cytotoxic effect on cancer cells (<em>P</em> &lt; 0.01).</div></div><div><h3>Conclusion</h3><div>CTSG inhibits BC malignancy and enhances CD8 + T cell function via EGFR/ERK inhibition.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 9","pages":"Pages 154-163"},"PeriodicalIF":2.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148817295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Technology in the Care of Breast-Cancer Related Lymphedema: A Scoping Review","authors":"Che-Chung Justin Lin,&nbsp;Ewa Zuzanna Krzyż","doi":"10.1016/j.clbc.2026.07.034","DOIUrl":"10.1016/j.clbc.2026.07.034","url":null,"abstract":"<div><div>Digital technologies are increasingly being incorporated into breast cancer-related lymphedema (BCRL) care, yet their role across the continuum of care has not been comprehensively synthesized. This scoping review mapped current applications of technology-assisted care for BCRL and identified key implementation considerations relevant to clinical practice. A scoping review was conducted following the Arksey and O'Malley framework and reported according to the Preferred Reporting Items of Systematic Reviews and Meta-analyses extension for Scoping Reviews guidelines. PubMed, Scopus, EMBASE, Web of Science, and MEDLINE were searched from inception to June 2026. Nineteen studies met the inclusion criteria. Digital technologies supported prevention, surveillance and monitoring, self-management, rehabilitation, and long-term follow-up. Frequently reported technologies included bioimpedance spectroscopy, three-dimensional imaging, mobile applications, telehealth, virtual reality, and remote monitoring tools. Most studies evaluated clinical outcomes, including limb volume, symptom severity, physical function, and quality of life, whereas implementation outcomes were less frequently assessed. Reported facilitators included improved accessibility, reduced travel burden, professional support, and enhanced patient engagement. Common barriers comprised technical challenges, limited digital literacy, unequal access to technology, and patient preference for face-to-face care. This review provides the first comprehensive overview of technology-assisted care across the BCRL continuum and highlights important gaps in implementation research. The findings support integrating digital technologies into patient-centered survivorship care while emphasizing the need for equitable, sustainable, and clinically integrated implementation strategies.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 9","pages":"Pages 164-170"},"PeriodicalIF":2.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148825791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Germline Pathogenic Variants in the Upgrade Rate to Breast Cancer Among Patients Diagnosed With Atypical Lobular Hyperplasia and Lobular Carcinoma In Situ on Core Needle Biopsy","authors":"Komal Ijaz,&nbsp;Broden Alston,&nbsp;Therese Bevers,&nbsp;Banu Arun,&nbsp;Diane Weber,&nbsp;Min Yi,&nbsp;Kelly Hunt,&nbsp;Gary Whitman,&nbsp;Lavinia P. Middleton","doi":"10.1016/j.clbc.2026.07.030","DOIUrl":"10.1016/j.clbc.2026.07.030","url":null,"abstract":"<div><h3>Introduction</h3><div>Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) are high-risk lesions that may be identified on biopsy performed for evaluation of radiologic abnormalities. Most women diagnosed with ALH and LCIS do not develop breast cancer. Treatment recommendations are ill-defined when these lesions are discovered in patients with germline pathogenic variants (PV) in breast cancer predisposition genes.</div></div><div><h3>Patients and Methods</h3><div>We reviewed our institutional databases and identified patients diagnosed on core needle biopsy (CNB) after screening mammography with lobular neoplasia (LN), including ALH and LCIS as their most significant pathology, and queried the electronic health record to identify those who had germline testing.</div></div><div><h3>Results</h3><div>In our cohort, among 70 patients who had informative genetic testing, where the majority of patients had a strong personal and family history of cancer, the prevalence of high- and moderate-penetrance germline PV carriers was 24.5%. Excision was performed in 40% of the patients with PV (<em>n</em> = 28). An upgrade to breast cancer was identified in 28.5%. All patients with an upgrade to cancer had both a PV and a family history of breast cancer.</div><div>Sixteen patients (17.2%) with LN and negative genetic testing underwent excision, and there were no upgrades to cancer (<em>P</em> = .04).</div></div><div><h3>Conclusion</h3><div>Patients with LCIS on core biopsy and known PVs demonstrated significant upgrade rates, supporting consideration of excision at the time of diagnosis. Knowledge of germline PV status along with clinical, pathologic and radiologic findings can potentially be used to de-escalate surgical therapy in individuals without germline PVs.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 9","pages":"Pages 193-198"},"PeriodicalIF":2.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148839630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Therapeutic Mammoplasty and Radiotherapy Side-effects","authors":"Arjuna Brodie,&nbsp;Ahmed Gaber,&nbsp;Monika Kaushik,&nbsp;Jaroslaw Krupa,&nbsp;Kelly V. Lambert,&nbsp;Simon M. Pilgrim,&nbsp;Walid Sasi,&nbsp;Kalliope Valassiadou,&nbsp;Kiran Kancherla,&nbsp;Kufre Sampson,&nbsp;Christopher J. Talbot,&nbsp;Tim Rattay","doi":"10.1016/j.clbc.2026.08.001","DOIUrl":"10.1016/j.clbc.2026.08.001","url":null,"abstract":"<div><h3>Introduction</h3><div>Patients with larger breast size and volume are at increased risk of side-effects (toxicity) from radiotherapy. Therapeutic mammoplasty (TM) extends breast-conserving surgery by combining wide local excision of the cancer with breast reduction and mastopexy techniques. The aim of this study was to determine the effect of TM using level 2 oncoplastic techniques on the incidence of early and long-term radiotherapy side-effects.</div></div><div><h3>Patients and Methods</h3><div>Breast cancer patients recruited prospectively into the multicenter REQUITE cohort study (<span><span>www.requite.eu</span><svg><path></path></svg></span>) at a single institution (n = 346) were included. Radiotherapy side-effects (CTCAE v4.0) were scored at baseline, following radiotherapy, and at 2-year follow-up. The association of TM and specimen resection weight were investigated in multivariable regression models.</div></div><div><h3>Results</h3><div>At 2 years, 20.1 % of patients had grade ≥ 2 atrophy, 23.2% grade ≥ 1 tumor bed induration (fibrosis), 12.6% grade ≥ 1 breast induration, and 12.1% grade ≥ 1 telangiectasia. 22.5 % of patients (n = 78) underwent TM. TM patients had larger tumors (<em>P</em> = .006) and specimen resection weights (<em>P</em> &lt; .001). TM but not specimen resection weight was associated with reduced tumor bed induration (Odds ratio = 0.12, 95% confidence interval [CI] 0.035-0.395, <em>P</em> = .001), breast induration (OR 0.19, CI 0.043-0.852, <em>P</em> = .03) and telangiectasia (OR 0.12, CI 0.020-0.736, <em>P</em> = .02). Neither TM nor specimen weight had any effect on atrophy or early radiotherapy side-effects.</div></div><div><h3>Conclusion</h3><div>TM but not resected specimen weight was associated with fewer long-term radiotherapy side-effects. This implies that the incidence of side-effects is affected not by reducing the overall radiotherapy target volume but by re-shaping the breast, which is likely to reduce dose inhomogeneity.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 9","pages":"Pages 199-203"},"PeriodicalIF":2.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Racial Differences in Psychological Distress and Problem Items among Breast Cancer Survivors at Adjuvant Endocrine Therapy Initiation","authors":"Fariha Tariq,&nbsp;Teletia Taylor,&nbsp;Dustin Bastaich,&nbsp;Vanessa B. Sheppard","doi":"10.1016/j.clbc.2026.07.001","DOIUrl":"10.1016/j.clbc.2026.07.001","url":null,"abstract":"<div><h3>Purpose</h3><div>The purpose of this study was to examine if there were racial differences in overall distress and problem items among Black and White breast cancer survivors at the time of adjuvant endocrine therapy (AET) initiation.</div></div><div><h3>Methods</h3><div>Data were analyzed from the Women’s Hormonal Initiation and Persistence study, an observational trial of hormone receptor-positive breast cancer survivors. Participants completed the National Comprehensive Cancer Network’s Distress Thermometer and its 36-item problem list. Multiple logistic regression was used to predict high distress (a score of ≥ 4 on the distress thermometer) by race, adjusting for sociodemographic and clinical characteristics. Descriptive statistics were computed by race (Black vs. White) for problem items reported by breast cancer survivors. χ2 tests were used to test racial differences in problem items.</div></div><div><h3>Results</h3><div>Of the 572 participants, 72% were White and 28% were Black. More than half of the sample (52%) reported high distress. Race was not a significant predictor of distress in either the univariate or the multivariable analysis. The top 5 problem items for the overall sample included <em>sleep</em> (50.5%), <em>fatigue</em> (48.6%), <em>worry</em> (41.6%), <em>dry/itchy skin</em> (39.9%), and <em>pain</em> (37.8%). There were no statistically significant differences in the problem items endorsed by Black and White breast cancer survivors.</div></div><div><h3>Conclusion</h3><div>Survivors reported high levels of distress and physical problem items at the time of AET initiation regardless of race. Future work should focus on the development of interventions targeting specific problem items that contribute to distress among breast cancer survivors on AET.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 8","pages":"Pages 131-136"},"PeriodicalIF":2.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148599866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Efficacy of Neoadjuvant Endocrine Therapy in HER2-Low Versus HER2-Negative Breast Cancer","authors":"Esther G. Chong,&nbsp;Mengni Guo,&nbsp;Kevin Bera,&nbsp;Dani Castillo,&nbsp;Peter Wu","doi":"10.1016/j.clbc.2026.07.003","DOIUrl":"10.1016/j.clbc.2026.07.003","url":null,"abstract":"<div><div>HER2-low breast cancer has emerged as a distinct biological subtype with implications for treatment response. However, its impact on response to neoadjuvant endocrine therapy (NET) in hormone receptor-positive (HR+) breast cancer remains unclear. The objective of this study is to evaluate whether HER2-low status is associated with improved clinical response to NET among patients with early-stage HR+ breast cancer.</div><div>A retrospective cohort study was conducted using data from the NCDB from 2010 to 2017, identifying women aged ≥ 18 years with stage I-III HR+ invasive breast cancer treated with NET, who had known HER2 immunohistochemistry status and response to NET documented. The primary outcome was clinical response to NET. We employed multivariable binomial logistic regression to examine how clinicopathologic factors influence the probability of any response to neoadjuvant hormonal therapy.</div><div>Among the 3808 women included, 1055 patients had HER2-negative disease, and 2753 patients were HER2-low. Among HER2-low patients, 37 had pathological complete response (CR), and 1097 had pathologic response (PR). Among HER2-negative patients, 11 had pathological CR, and 387 had PR. Multivariable logistic models revealed that age, duration of NET, and HER2 status were significant predictors of any response to NET. HER2-low tumors were more likely to have any response compared to HER2-negative. HER2-low status had improved response to NET among women with early-stage HR+ breast cancer, which supports the concept of HER2-low disease as a distinct therapeutic entity and may inform individualized treatment strategies for endocrine-based therapies.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 8","pages":"Pages 189-195"},"PeriodicalIF":2.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148643893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patients With Luminal Breast Carcinoma: The State of the Field in Proteomic and Proteogenomic Molecular Subtyping","authors":"Michal Alexovič,&nbsp;Ján Sabo,&nbsp;Pavel Bouchal","doi":"10.1016/j.clbc.2026.06.014","DOIUrl":"10.1016/j.clbc.2026.06.014","url":null,"abstract":"<div><div>The subtyping of breast carcinoma (BC) is essential for an accurate diagnosis, prognosis, and treatment decisions. Histopathological evaluation and immunohistochemical analysis are standard methods for clinical stratification of patients with BC. Gene expression profiling (such as PAM50) can further provide a more comprehensive tumor description by examining disease-related processes at the transcript level. As such molecular events may not necessarily culminate in the synthesis of a mature proteins, proteomic analysis can help to reveal key molecular signatures, post-translational modifications, signaling pathways, and protein–protein interaction networks for even better characterization of the tumor and its microenvironment. Ultimately, by combining next-generation DNA and RNA sequencing with proteomic profiling toward an integrative proteogenomic framework, expressed mutant genes, copy number alterations, reconstructed RNA transcripts, alternative splicing events, and novel candidate biomarker proteins can be systematically analyzed. In this work, proteomic and proteogenomic studies (2015-2025) of luminal breast carcinoma (Lum BC) subtypes performed on tissues and body fluids were systematically reviewed with the aim of discussing protein signatures and molecular pathways they regulate, while the provided tables describe and compare the experimental platforms used. Future research must balance experimental complexity, proteomic and proteogenomic depth, and the time and cost of large-scale longitudinal studies while still producing datasets of sufficient quality. Here, emerging analyses of tumor-derived blood samples can provide “non-invasive” candidate biomarker proteins that may compete with tissue-derived protein signatures.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 8","pages":"Pages 96-111"},"PeriodicalIF":2.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148583647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Timing and Format of Patient Decision Aids on Involvement in Shared Decision-Making for Patients With Breast Cancer: The IMPACTT Randomized, Controlled Study","authors":"Bettina Mølri Knudsen,&nbsp;Stine Rauff Søndergaard,&nbsp;Lea Lund,&nbsp;Karina Dahl Steffensen,&nbsp;Dawn Stacey","doi":"10.1016/j.clbc.2026.07.002","DOIUrl":"10.1016/j.clbc.2026.07.002","url":null,"abstract":"<div><h3>Background</h3><div>For people with breast cancer facing adjuvant treatment decisions, it is unclear whether providing a patient decision aid (PtDA) before versus during the consultation leads to greater involvement in shared decision-making (SDM). The overall aim was to evaluate the effect of a digital preconsult PtDA compared with an identical in-consult paper-based PtDA.</div></div><div><h3>Patients and Methods</h3><div>In this randomized controlled trial, patients with breast cancer eligible for adjuvant treatment were randomized to a digital PtDA before consultation or a paper-based PtDA during consultation. Primary outcome was patient-reported SDM Process_4. Secondary outcomes included observer-rated SDM (OPTION5/12), patient- and physician-reported SDM-Q, decisional conflict, CollaboRATE, preparation for decision-making, and consultation duration. Between-group differences were estimated using linear regression; post-consultation outcomes were analyzed with standard errors clustered at the physician level.</div></div><div><h3>Results</h3><div>A total of 204 patients were randomized. Mean SDM Process_4 score was lower in the preconsult group, but not significant (<em>P</em> = .154). Observer-rated SDM was significantly higher in the in-consult group (OPTION5; <em>P</em> = .019; OPTION12: <em>P</em> = .005). The preconsult group reported lower decisional conflict before the consultation (<em>P</em> = .002) and lower preparation for decision-making (<em>P</em> = .004). No significant between-group differences were observed for post-consultation decisional conflict, SDM-Q, CollaboRATE, or consultation duration.</div></div><div><h3>Conclusions</h3><div>Patient-reported SDM did not differ significantly between groups, but the paper-based in-consult PtDA was associated with higher observer-rated SDM. Digital PtDAs may reduce decisional conflict before consultation, but structured integration into the encounter may be needed to support observable SDM.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 8","pages":"Pages 180-188"},"PeriodicalIF":2.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148629644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Cancer Location Predicts Sentinel Lymph Node Metastasis in Clinically Node Negative Patients With Invasive Breast Cancer Treated With Upfront Surgery","authors":"Nazia Riaz,&nbsp;Nizar AbuOddus,&nbsp;Hafsteinn Peturson,&nbsp;Fredrik Wärnberg,&nbsp;Roger Olofsson Bagge","doi":"10.1016/j.clbc.2026.06.013","DOIUrl":"10.1016/j.clbc.2026.06.013","url":null,"abstract":"<div><h3>Background</h3><div>Assessment of clinicopathological factors is standard for predicting the sentinel lymph node (SLN) status in patients with clinically node negative breast cancer. Limited studies have specifically addressed the value of cancer location as an independent factor predicting SLN status. This study aimed to evaluate whether clinicopathological factors, and specifically cancer location, predict SLN status.</div></div><div><h3>Methods</h3><div>This retrospective study was performed in a cohort of consecutive patients diagnosed with T1 to T3 clinically node negative invasive breast cancer managed at a single institution between 2003 and 2008. All underwent SLN biopsy as part of their primary surgery. Multivariable logistic regression was performed to assess the value of clinicopathological factors, including tumor location, for predicting SLN metastasis.</div></div><div><h3>Results</h3><div>A total of 1231 patients were included with a median age of 60 years and median tumor size of 19 mm. The majority (78%) of tumors were estrogen receptor positive. SLN was positive in 17.6% patients. Multivariable logistic regression showed that age (odds ratio [OR] 0.98, 95% confidence interval [CI] 0.97-1.00; <em>P</em> = .03), tumor size (OR 1.04, 95% 1.03-1.05; <em>P</em> &lt; .001), and location, specifically inferior-lateral (OR 0.40, 95% CI 0.20-0.84; <em>P</em> = .01), and superior-medial (OR 0.54, 95% CI 0.31-0.97; <em>P</em> = .04) quadrant, were factors significantly associated with SLN status.</div></div><div><h3>Conclusion</h3><div>Tumor location within the breast was an independent risk factor for SLN metastasis. Therefore, considering cancer location in addition to standard clinicopathological factors can be an important factor when selecting patients for future de-escalation of axillary surgery.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 8","pages":"Pages 90-95"},"PeriodicalIF":2.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148548055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Prognostic Utility of CPS+EG, Neo-Bioscore, and Conventional Staging Systems in Breast Cancer Patients Without Pathological Complete Response to Neoadjuvant Chemotherapy","authors":"Tingting Deng,&nbsp;Huiling Xiang,&nbsp;Xiao Luo,&nbsp;Cuiju Yan,&nbsp;Lanxia Zhang,&nbsp;Qingguang Lin,&nbsp;Jinjing Ou,&nbsp;Chunyan Li,&nbsp;Fei Xu,&nbsp;Rongzhen Luo,&nbsp;Xi Lin","doi":"10.1016/j.clbc.2026.07.004","DOIUrl":"10.1016/j.clbc.2026.07.004","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer patients with non-pathologic complete response (non-pCR) after neoadjuvant chemotherapy (NAC) exhibit heterogeneous outcomes. While the CPS+EG and Neo-Bioscore staging systems integrate clinical, pathological, and biologic factors to improve post-NAC prognostication, their utility in the non-pCR cohort warrants further evaluation. This study aimed to compare their prognostic performance with traditional clinical (CS) and pathologic stage (PS).</div></div><div><h3>Materials and Methods</h3><div>This retrospective single-center study included 784 non-pCR breast cancer patients after NAC. Prognostic discrimination of CS, PS, CPS+EG, and Neo-Bioscore for DFS and OS was assessed by Kaplan–Meier analysis and concordance index (C-index). Subgroup analyses were performed by molecular subtype. An exploratory comparison with Residual Cancer Burden (RCB) was conducted in a subset of 167 patients with available RCB scores.</div></div><div><h3>Results</h3><div>In the overall cohort, both CPS+EG and Neo-Bioscore provided superior prognostic stratification for DFS and OS compared to CS or PS alone (all C-index comparisons <em>P</em> &lt; .001 vs. CS). Their performance was subtype-dependent. In HR-positive/HER2-negative and HER2-positive subtypes, CPS+EG and Neo-Bioscore showed significantly better prognostic value. However, in triple-negative breast cancer, neither composite score offered significant stratification, where PS emerged as the most robust predictor. In the RCB-available subset, RCB did not significantly stratify DFS or OS, whereas both CPS+EG and Neo-Bioscore showed significant associations with DFS.</div></div><div><h3>Conclusions</h3><div>The CPS+EG and Neo-Bioscore systems offer refined prognostic stratification for non-pCR patients, outperforming conventional staging systems in most subtypes. These readily available tools provide a practical framework for risk-adapted adjuvant therapy planning in the postneoadjuvant setting, though further prospective validation is warranted.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 8","pages":"Pages 172-179"},"PeriodicalIF":2.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148629661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}